Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PSMA-targeted PET ligand
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Peptides
- Administration
- Intravenous
01
Overview
PSMA-targeted PET ligands are a class of radiolabeled small molecules or antibodies designed to bind specifically to prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII) or folate hydrolase 1 (FOLH1). These ligands are labeled with positron-emitting radionuclides (such as Gallium-68 or Fluorine-18) to enable high-resolution positron emission tomography (PET) imaging. While primarily utilized for the detection, staging, and restaging of prostate cancer, PSMA-targeted PET ligands are increasingly being investigated for imaging non-prostatic malignancies, including primary and metastatic central nervous system (CNS) tumors, where PSMA is often highly expressed in the tumor neovasculature.
- Other names
- prostate-specific membrane antigen-targeted PET ligandPSMA PET ligandPSMA PET tracerPSMA-targeted PET tracerPSMA-targeted radioligand
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on PSMA-targeted PET ligand.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PSMA-targeted PET ligand.